Viking Therapeutics
VKTX
12 hedge funds and large institutions have $1.69M invested in Viking Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more capital invested
Capital invested by funds: $1.13M → $1.69M (+$567K)
2.43% more ownership
Funds ownership: 3.23% → 5.67% (+2.4%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
Top Sellers
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$23.4K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$18K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 4 |
Morgan Stanley
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $525K | +$619K | +486,491 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $357K | – | – | – |
|
3
Renaissance Technologies
New York
| $323K | +$42.2K | +33,200 | +12% |
|
|
PWAM
4
Park West Asset Management
San Francisco,
California
| $216K | +$254K | +200,000 | New |
|
|
VKH
5
Virtu KCG Holdings
New York
| $124K | +$146K | +114,507 | New |
|
|
SKK
6
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $92K | -$23.4K | -18,408 | -18% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $33K | – | – | – |
|
8
Northern Trust
Chicago,
Illinois
| $18K | – | – | – |
|
9
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2K | +$232 | +182 | +10% |
|
|
AG
10
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
11
BlackRock
New York
| $1K | – | – | – |
|
|
RFA
12
Reilly Financial Advisors
La Mesa,
California
| $1K | – | – | – |
|
|
AIM
13
Acrospire Investment Management
Chicago,
Illinois
| – | -$18K | -12,642 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$7K | -4,506 | Closed |
|
|
15
Morgan Stanley
New York
| – | -$1K | -398 | Closed |
|
VKTX Hedge Fund Activity: Q2 2017 in Review
12 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2017, worth a combined $1.69M — up 50% from $1.13M a quarter earlier.
Fund positioning in VKTX was balanced in Q2 2017: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $619K. The largest seller was Shepherd Kaplan Krochuk, cutting an estimated $23.4K.
- 12 institutional investors held Viking Therapeutics (VKTX) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $1.69M of Viking Therapeutics stock for Q2 2017, up 50% quarter-over-quarter.
- 3 funds opened new Viking Therapeutics positions in Q2 2017 and 3 closed out, a net change of 0 holders.
- The largest Viking Therapeutics buyer in Q2 2017 was Sabby Management, an estimated $619K added.
- The largest Viking Therapeutics seller in Q2 2017 was Shepherd Kaplan Krochuk, an estimated $23.4K sold.
Based on aggregated 13F filings for Q2 2017.